Monday 2 November 2015
Big data
Benchmarking and biomarkers: the molecular and technical heterogeneity of prostate cancer
Molecular archaeology of cancer
Understanding genome organisation:using HiC data to interpret gene regulation and non-coding mutations
Chromatin, epigenetics and cancer
Introduction: Chromatin, epigenetics and cancer
Epigenetic targets for cancer drug discovery: bromodomains and beyond
Epigenetic reprogramming in mammalian development
Epigenetics impacts copy number heterogeneity and drug resistant gene selection
Immunotherapy
Gut microbiota and anti-cancer immune responses
The mechanistic basis of cancer immunotherapy
T cells and the immunogenicity of immunotherapy
Molecular testing in cancer screening: ready for prime time
Working together in the genomics era: lessons from the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study
Molecular biomarkers: are they so much better than traditional risk factors and simple biomarkers?
Devising the ideal test for early diagnosis of cancer: lessons from the oesophagus
Tuesday 3 November 2015
DNA repair and cancer
Protective packaging for DNA: the role of the PBAF and INO80 chromatin remodelling complexes in maintaining genome stability
Role of the BRCA1:BARD1 ubiquitin ligase activity in DNA repair
Genetic dissection of tumour development, therapy response and resistance in mouse models of BRCA1-deficient breast cancer
Genomics and cancer evolution
Phylogenetic analysis reveals divergent modes of clonal spread and intraperitoneal mixing in high grade serous ovarian cancer
Evolution and drug resistance in cancer
Tracking tumour evolution with clonal assays: mutation order matters
Lifestyle behaviour and cancer prevention
Introduction: Lifestyle behaviour and cancer prevention
How many cancers can we prevent through dietary modifications?
Reducing exposure to alcohol to reduce cancer risk
Physical activity, obesity and cancer
Molecular imaging and radionuclide therapy
Molecularly targeted radiation therapy: towards individualised treatment
Translating novel diagnostic and therapeutic radiopharmaceuticals into the clinic
Radium-223 for prostate cancer bone metastases: how research can change clinical practice